NVSEF - FSD Pharma Jumps On COVID-19 Trial Progress And Other News: The Good Bad And Ugly Of Biopharma
FSD Pharma Stock Jumps on FDA Nod for COVID 19 Trial
FSD Pharma Inc. (HUGE) announced that the FDA has provided its approval to the company for the design of its COVID-19 trial. The approval now allows the company to submit an Investigational New Drug Application for using its drug candidate FDS-201 for treating COVID-19 patients. The drug candidate aims to control the cytokine storm related to the acute lung injury in hospitalized COVID-19 patients.
The trial is expected to be a randomized, controlled and double-blind multi-center study. The main aim of the